Welcome to our dedicated page for Galata Acquisition II SEC filings (Ticker: LATAU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Galata Acquisition II's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Galata Acquisition II's regulatory disclosures and financial reporting.
Galata Acquisition Sponsor II, LLC reports beneficial ownership of 5,750,000 Class B Ordinary Shares, which convert one-for-one into Class A Ordinary Shares. The filing states the 5,750,000 shares represent 25.0% of the Class A share count when assuming conversion, based on 17,250,000 Class A Ordinary Shares issued and outstanding as of November 13, 2025.
The filing names Galata Acquisition Sponsor II, LLC as record holder and discloses that Daniel Freifeld (issuer Chairman and CIO) is managing member of Callaway Capital Management, LLC and holds voting and investment discretion for the sponsor; Mr. Freifeld disclaims beneficial ownership except to the extent of any pecuniary interest.
AQR Capital Management entities have updated their ownership report for Galata Acquisition Corp. II. In this amended Schedule 13G, AQR Capital Management, LLC, AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC report beneficial ownership of 677,427 Class A ordinary shares as of 12/31/2025.
This position represents 3.93% of Galata’s Class A shares. The AQR entities report shared voting and dispositive power over all 677,427 shares, with no sole voting or dispositive power. They certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Galata Acquisition Corp. II.
Galata Acquisition Corp. II filed its quarterly report as a newly public SPAC. The company completed its IPO, selling 17,250,000 units at $10.00 each, and placed $172,500,000 into a U.S. trust account. Class A ordinary shares are redeemable at $10.01 per share as of September 30, 2025.
Cash held outside the trust was $1,098,128 to fund search and operating needs, with a deferred underwriting fee of $6,037,500 payable only upon a business combination. For the quarter, Galata reported net income of $43,587, driven by $151,164 of interest on trust investments and $107,577 of operating and formation costs.
There are 11,050,000 warrants outstanding (5,750,000 public and 5,300,000 private), each exercisable for one Class A share at $11.50. The company has until September 22, 2027 to complete a business combination, after which it will redeem public shares. As of November 13, 2025, shares outstanding were 17,250,000 Class A and 5,750,000 Class B.
Galata Acquisition Corp. II announced that, starting November 10, 2025, holders of its units (ticker LATAU) may separately trade the underlying Class A ordinary shares and redeemable warrants. Each unit comprises one Class A ordinary share and one-third of one warrant; each whole warrant is exercisable for one Class A ordinary share at $11.50 per share. Only whole warrants will trade.
The Class A ordinary shares and warrants are expected to trade on the Nasdaq Global Market under LATA and LATAW, respectively. To separate units, holders should have their brokers contact Continental Stock Transfer & Trust Company, the transfer agent.